Toivo Maimets - Selected publications#
1. Villems R., Koger A., Lind A., Maimets T., Metspalu E., Saarma M., Sarapuu T., Ustav M. Affinity chromatography of Escherichia coli ribosomal protein on the immobilized ribonucleic acids. Properties of the complexes. Biological implications of protein- nucleic acid interactions. (J.Augustyniak ed.) Elsevier/North Holland Biomedical Press, Amsterdam, N.Y., Oxford, Poznan. (1980) 91-99.
2. Metspalu E., Maimets T., Ustav M., Villems R. A quarternary complex consisting of two molecules of tRNA and ribosomal pro¬teins L2 and Ll7. FEBS Lett. (1981) 132, 105-108.
3. Sedman J., Maimets T., Ustav M., Villems R. The interaction of 5S RNA and its large fragments with ribosomal proteins. FEBS Lett. (1981) 136, 251-254.
4. Maimets T.O., Ustav M.B., Villems R.L.-E., Saarma M.J., Lind. A.J. Binding of Escherichia coli 50 S ribosomal subunit proteins with two large 5S RNA fragments. Molecular Biology (USSR) (1981) 6, 569-574.
5. Metspalu E., Ustav M., Maimets T., Villems R. The composition and properties of the Escherichia coli 5S RNA-protein complex. Eur. J. Biochem. (1982) 121, 383-389.
6. Maimets T., Ustav M., Villems R. The role of protein L16 and its fragments in the peptidyltransferase activity of 50-S riboso¬mal subunits. Eur. J. Biochem. (1983) 135, 127-130.
7. Remme J., Maimets T., Ustav M., Villems R. The interaction of ribosomal protein L16 and its fragments with tRNA. FEBS Lett. (1983) 153, 267-269.
8. Maimets T., Remme J., Villems R. Ribosomal protein L16 binds to the 3'-end of transfer RNA. FEBS Lett. (1984) 166, 53-56.
9. Maimets T.O., Ustav M. B., Remme J.L.,Villems R.L.-E. E.coli ribosomal protein L16: its possible role in protein biosynthesis. Molecular Biology (USSR) (1984) 18, 1597-1605.
10. Remme J., Metspalu E., Maimets T., Villems R. The properties of the complex between ribosomal protein L2 and tRNA. FEBS Lett. (1985) 190, 275-278.
11. Maimets T.O., Remme J.L., Villems R.L.-E. Stimulation of peptidyltransferase activity of 50S subunits with alcohols. Molecular Biology (USSR) (1985) 3, 617-622.
12. Saarma R.J., Maimets T.O., Anton R.G., Lind A.J. Studies on ras-family oncogenes in tumors of human brain. In: Actual problems of neurology and neurosurgery. Tartu University Press. (1986) 165- 170.
13. Maimets T.O., Jenkins J.R. Modified oncoprotein p53 in HT1080 tumor cell line. Proc. USSR Acad. Sci. (1987) 296, 757-759.
14. Sturzbecher H.-W., Brain R., Maimets T., Addison C., Rudge K., Jenkins J. Mouse p53 blocks SV40 DNA replication in vitro and downregulates T antigen DNA helicase activity. Oncogene (1988) 3, 101-109.
15. Maimets T.O. Bacterial expression of human p53 oncogene as a fusion protein. Proc. USSR Acad. Sci. (1988) 302, 1501-1503.
16. Jenkins J.R., Stürzbecher H.-W., Brain R., Grimaldi M., Mai¬mets T., Rudge K., Court W., Addison C. Identification and analy¬sis of human p53 mutants which are trans-dominant modulators of DNA replication in vivo. Cancer Cells (1989) 7, 127-135.
17. Stürzbecher H.-W., Maimets T., Chumakov P., Brain R., Addison C., Simanis V., Rudge K., Philp R., Grimaldi M., Court W., Jenkins J. p53 interacts with p34cdc2 in mammalian cells: implications for cell cycle control and oncogenesis. Oncogene (1990) 5, 795-801.
18. Wagner P., Simanis V., Maimets T., Keenan E., Addison C., Brain R., Grimaldi M., Sturzbecher H.- W., Jenkins J. A human tumour-derived mutant p53 protein induces a p34cdc2 reversible growth arrest in fission yeast. Oncogene (1991) 6, 1539-1547.
19. Montesano R., Fuchs R., Vogel E., Bignami M., Maimets T. Environmental carcinogens and mutation spectra in p53 tumour suppressor gene and other critical genes. In: A Review of Research in Environmental Health & Chemical Safety in the STEP & ENVIRONMENT Research Programmes. Ecosystems Research Report (1995) 15, 111 - 113.
20. Kristjuhan A., Maimets T. Protein P53 modulates transcription from a promoter containing its binding site in concentration-dependent manner. Eur. J. Biochem. (1995) 234, 827 - 831.
21. Kristjuhan A., Jaks V., Rimm I., Tooming T., Maimets T. Oligomerization of p53 is necessary to inhibit its transcriptional transactivation property at high protein concentration. Oncogene (1998) 16, 2413-2418.
22. Lepik D., Ilves I., Kristjuhan A., Maimets T., Ustav M. p53 protein is a suppressor of papillomavirus DNA amplificational replication. J. Virol. (1998) 72, 6822-6831.
23. Jõers A., Kristjuhan A., Kadaja L., Maimets T. Tumour associated mutants of p53 can inhibit transcriptional activity of p53 without heterooligomerization. Oncogene (1998) 17, 2351-2358.
24. Maimets T. Molekulaarne rakubioloogia. Ilmamaa 1999, 248 lk.
25. Kadaja L., Jesnowski R., Maimets T., Liebe S., Lohr M. Construction of recombinant retroviruses expressing mutated k-ras or mutated p53 genes. Ann N Y Acad Sci (1999) 880, 371-373.
26. Maimets T. Valgu p53 kasutusvõimalused molekulaarse markerina erinevate kasvajate puhul (Protein p53 as a molecular marker for different human tumours, in estonian) Eesti Arst (2000)1, 34- 43.
27. Jaks V., Jõers A., Kristjuhan A., Maimets T. p53 protein accumulation in addition to its transcriptional activation is required for p53-dependent cell cycle arrest after treatment of cells with camptothecin. Oncogene (2001) 20, 1212-1219.
28. Krinka D., Raid R., Pata I., Kärner J., Maimets T. In Situ hybridization of chick embryos with p53- specific probe and their immunostaining with anti-p53 antibodies. Anat. Embryol. (2001) 204, 207 – 215.
29. Lepik D., Jaks V., Värv S., Kadaja L., Maimets T. Electroporation and carrier DNA cause p53 activation, cell cycle arrest and apoptosis. Analytical Biochemistry (2003), 318, 52-59.
30. Kadaja L, Laos S, Maimets T. Overexpression of leukocyte marker CD43 causes activation of the tumor suppressor proteins p53 and ARF. Oncogene (2004) 23, 2523-2530.
31. Joers A., Jaks V., Kase J., Maimets T. p53-dependent transcription can exhibit both on/off and graded response after genotoxic stress. Oncogene (2004) 23,6175-6185.
32. Pauklin S, Kristjuhan A, Maimets T, Jaks V. ARF and ATM/ATR cooperate in p53-mediated apoptosis upon oncogenic stress. Biochem Biophys Res Commun. (2005) 334, 386-394.
33. Maimets T. Kas siniste silmade, valgete õite ja haiguste geenid on olemas? (Do genes for blue eyes, white flowers and diseases exist? in estonian) Akadeemia (2005), 11, 2344-2384.
34. Maimets T. Juhuslikkusest rakkude elus. Horisont (2006), 2, 31-35.
35. Kallas A, Kuuse S, Maimets T, Pooga M. von Willebrand factor and transforming growth factorbeta modulate immune response against coagulation factor VIII in FVIII-deficient mice. Thromb Res. (2007) 120, 911-919.
36. Kadaja-Saarepuu L., Laos S., Jääger K., Viil J., Balikova A., Lõoke M., Hansson G.C. and Maimets T. CD43 promotes cell growth and helps to evade FAS-mediated apoptosis in nonhematopoietic cancer cells lacking the tumor suppressors p53 or ARF. Oncogene (2008) 27, 1705-1715.
37. Johansson H.J., El-Andaloussi S., Holm T., Mäe M., Jänes J., Maimets T. and Langel Ü. Characterization of a novel cytotoxic cell-penetrating peptide derived from p14ARF protein. Molecular Therapy (2008) 16, 115-123.
38. Maimets T., Neganova I., Armstrong L. and Lako M. Activation of p53 by nutlin leads to rapid differentiation of human embryonic stem cells. Oncogene (2008) 27, 5277-5287.
39. Kallas A., Kuuse S., Maimets T., Pooga M. Von Willebrand factor-specific antibodies developing upon treatment of FVIII-deficient mice with different FVIII preparations. Acta Haematologica (2008) 119, 244-247.
40. Maimets T. Millal algab inimese elu? (When does human life begin? in estonian). Akadeemia (2008) 8, 1671-1694.
41. Bonaccorsi A., Horvat M., Maimets T., Papon P. (2008). The Report of the Expert Group on the Future of Networks of Excellence. EU DG Research, Brussels, September 2008, 49 pp. http://ec.europa.eu/research/index.cfm?lg=en&pg=reports
42. Monfret J., Fenger P., Kotilainen H., Maimets T., Luz Peñacoba M., Boekholt P. Final Review of COST in the Sixth Framework Programme. EU DG Research Brussels, May 2007, 24 pp. ftp://ftp.cordis.europa.eu/pub/coordination/docs/cost_final_review_en.pdf
43. Maimets, T.; Levy-Lahad, E.; Hu, Q.; Serour, G.; Stepke, F. (2009). Report of IBC on Human Cloning and International Governance. UNESCO, Paris: UNESCO
44. Maimets T (2009). Thomas Hunt Morgan, moodsa geneetika isa. - Lehed ja tähed V (I. Rohtmets ja T. Kukk toim.), lk. 156-161.
45 Schneider C.K., Salmikangas P., Jilma B., Flamion B., Racheva. Todorova L, Paphitou A., Haunerova I., Maimets T., Trouvin J.-H. , Flory E., Tsiftsoglou A., Sarkadi B., Gudmundsson K., O'Donovan M., Migliaccio G., Ancans J., Mačiulaitis R., Robert J.-L., Samuel A., Ovelgönne J.H., Hystad M., Fal A.M., Silva Lima B., Moraru A.S., Turčáni P., Zorec R., Ruiz S., Åkerblom L., Narayanan G., Kent A., Bignami F., Dickson J.G., Niederwieser D., María-Angeles Figuerola-Santos M.-A., Reischl I.G., Beuneu C., Georgiev R., Vassiliou M., Pychova A., Clausen M., Methuen T., Lucas S., Schüssler-Lenz M., Kokkas V., Buzás Z., MacAleenan N., Galli M.C., Linē A., Gulbinovic J., Berchem G., Frączek M., Menezes-Ferreira M., Vilceanu N., Hrubiško M., Marinko P., Timón M., Cheng W., Crosbie G.A., Meade N., Lipucci di Paola M., VandenDriessche T., Ljungman P., D'Apote L., Oliver-Diaz O., Büttel I., Celis P.. Challenges with advanced therapy medicinal products and how to meet them. Nature Reviews Drug Discovery (2010) 9, 195-201.
46. Annerberg, R.; Begg, I.; Acheson, H.; Borras, S.; Hallen, A.; Maimets, T.; Mustonen, R., Raffler, H.; Swings, J.-P.;Ylihonko, K. (2010). Interim evaluation of the Seventh Framework Programme. Report of the expert group. EU DG Research, Brussels: EU DG Research
47. Kallas A, Kuuse S, Maimets T, Pooga M. Naturally occurring CD4+ CD25+ cells in modulating immune response to administered coagulation factor VIII in factor VIII-deficient mice. Haemophilia. 2011 Jan;17(1):143-51.
48. Kallas, A., Pook, M., Maimets, M., Zimmermann, K., Maimets, T. (2011). Nocodazole treatment decreases expression of pluripotency markers Nanog and Oct4 in human embryonic stem cells. PLoS One 2011 Apr 29;6(4):e19114.
49. Maimets, T (2011). Kasvajate tüvirakud – kas mõtteviisi muutus? Eesti Arst, 90(10), 474 - 480.
50. Kadaja-Saarepuu, L.; Lõoke, M.; Balikova, A.; Maimets, T. (2012). Tumor suppressor p53 downregulates expression of human leukocyte marker CD43 in non-hematopoietic tumor cells. International Journal of Oncology, 40(2), 567 - 576.
51. Balikova A, Jääger K, Viil J, Maimets T, Kadaja-Saarepuu L. Leukocyte marker CD43 promotes cell growth in co-operation with β-catenin in non-hematopoietic cancer cells. Int J Oncol. 2012 Jul;41(1):299-309.
52. Teino I, Kuuse S, Ingerpuu S, Maimets T, Tiido T. The aryl hydrocarbon receptor regulates mouse Fshr promoter activity through an e-box binding site. Biol Reprod. 2012 Mar 22;86(3):77.
53. Maimets, Toivo (2012). A Changing Scene. Public Service Review: UK Science and Technology, 6, 16 - 17.
54. Maimets, Toivo (2013). 2013. aasta Nobeli meditsiinipreemia rakusisese transpordikorralduse mõistmise eest. Eesti Arst, 92(10), 552 - 553.
55. Maimets, Toivo (2012). Teaduse teed. Tartu: Ilmamaa, 272 lk.
56. Maimets, Toivo (2012). Nobeli meditsiini- ja keemiapreemia 2012. aasta laureaatide panus arstiteaduse arengusse. Eesti Arst, 91(10), 525 - 528.
57. Teino, Indrek; Matvere, Antti; Kuuse, Sulev; Ingerpuu, Sulev; Maimets, Toivo; Kristjuhan, Arnold; Tiido, Tarmo (2014). Transcriptional repression of the Ahr gene by LHCGR signaling in preovulatory granulosa cells is controlled by chromatin accessibility. Molecular and Cellular Endocrinology, 382, 292-301.
58. Pook M, Tamming L, Padari K, Tiido T, Maimets T, Patarroyo M, Juronen E, Jaks V, Ingerpuu S. Platelets store laminins 411/421 and 511/521 in compartments distinct from α- or dense granules and secrete these proteins via microvesicles. (2014) J Thromb Haemost. 12, 519-27.
59. Kallas A, Pook M, Trei A, Maimets T(2014). SOX2 is regulated differently from NANOG and OCT4 in human embryonic stem cells during early differentiation initiated with sodium butyrate. Stem Cells International, 298163. doi: 10.1155/2014/298163. Epub 2014 Feb 19.
60. Maimets, Toivo; Lõuk, Kristi (2014). Human cloning. Henk ten Have, Bert Gordijn (Eds.). Compendium & Atlas of Global Bioethics 699-718.Springer .
61. Maimets T (2014). Kas peale “geeni” on olemas ka “epigeen”? Akadeemia 26(10):1827-1846.
62. Maimets, Toivo (2015). Induced pluripotency for the study of disease mechanisms and cell therapy. In: Advances in Predictive, Preventive and Personalised Medicine. Rare Diseases: Integrative PPPM Approach as the Medicine of the Future. Prof. Dr. Meral Özgüc (Ed.), pp. 159-173, Springer.
63. Ade Kallas, Martin Pook, Annika Trei and Toivo Maimets (2014). Assessment of the potential of CDK2 inhibitor NU6140 to influence the expression of pluripotency markers NANOG, OCT4 and SOX2 in 2102Ep and H9 cells. International Journal of Cell Biology, Article ID 280638, doi:10.1155/2014/280638,1 - 16.
64. Toivo Maimets and Kristi Lõuk. Cloning:human. In: Encyclopedia of Global Bioethics. Henk ten Have (ed.). Springer.
65. Maimets T., Tiido T. (2014). Uudsed ravimid. Eesti Arst 2014; 93(11):650–653.
16.12.2014
